Context Therapeutics, Inc. (DE:6K9)
NASDAQ:6K9
6K9 Stock Chart & Stats
€1.88
-€0.07(-6.42%)
At close: 4:00 PM EST
€1.88
-€0.07(-6.42%)
Day’s Range― - ―
52-Week Range€0.44 - €3.12
Previous CloseN/A
Volume0.00
Average Volume (3M)159.00
Market Cap
€191.53M
Enterprise Value€207.61M
Total Cash (Recent Filing)€54.53M
Total Debt (Recent Filing)€282.42K
Price to Earnings (P/E)―
Beta-0.03
Next Earnings
Aug 12, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.42
Shares Outstanding91,879,170
10 Day Avg. Volume0
30 Day Avg. Volume159
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.31
Price to Sales (P/S)0.00
P/FCF Ratio-5.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€5.46Price Target Upside190.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.32
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
FDA Fast Track For CTIM-76Fast Track designation is a durable regulatory advantage that can accelerate interactions with FDA and potentially shorten development timelines. For a clinical-stage oncology biotech, this reduces regulatory uncertainty, improves partnership value, and materially supports long-term program de-risking.
Full Rights To Antibody AssetsOwning irrevocable, royalty-free, non-terminable licenses materially improves asset economics and strategic optionality. It removes future milestone/royalty burdens and counterparty termination risk, enabling Context to prioritize or out-license CT-202 and align capital toward clinical execution.
Concentrated T-cell Engager PipelineA focused, multi-asset TCE pipeline with near-term Phase 1 milestones provides durable R&D leverage: multiple shots-on-goal in a growing immuno-oncology segment, potential for combinations, and clearer development priorities that strengthen long-run commercialization prospects if early clinical signals emerge.
Bears Say
No Revenue; Widening LossesThe company has no product revenue and sustained widening net losses, a structural constraint for biotech that increases reliance on external capital. Continued losses erode equity, produce negative ROEs, and limit strategic flexibility absent clear near-term routes to commercialization or deal funding.
Persistent Cash Burn And Negative FCFMaterial, recurring negative operating and free cash flow shortens runway and necessitates recurrent financing. This creates dilution risk, constrains the company’s ability to scale trials independently, and can force suboptimal partnering or program prioritization decisions over the medium term.
Governance Litigation And CostA governance lawsuit that required charter corrections and an $850k mootness payment signals governance weaknesses and creates lasting oversight changes. Such events can distract management, impose unexpected costs and elevate shareholder activism or turnover risk, affecting strategic continuity.
Context Therapeutics News
6K9 FAQ
What was Context Therapeutics, Inc.’s price range in the past 12 months?
Context Therapeutics, Inc. lowest stock price was €0.44 and its highest was €3.12 in the past 12 months.
What is Context Therapeutics, Inc.’s market cap?
Context Therapeutics, Inc.’s market cap is €191.53M.
When is Context Therapeutics, Inc.’s upcoming earnings report date?
Context Therapeutics, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 69 days.
How were Context Therapeutics, Inc.’s earnings last quarter?
Context Therapeutics, Inc. released its earnings results on May 06, 2026. The company reported -€0.078 earnings per share for the quarter, beating the consensus estimate of -€0.096 by €0.018.
Is Context Therapeutics, Inc. overvalued?
According to Wall Street analysts Context Therapeutics, Inc.’s price is currently Undervalued.
Does Context Therapeutics, Inc. pay dividends?
Context Therapeutics, Inc. does not currently pay dividends.
What is Context Therapeutics, Inc.’s EPS estimate?
Context Therapeutics, Inc.’s EPS estimate is -0.07.
How many shares outstanding does Context Therapeutics, Inc. have?
Context Therapeutics, Inc. has 91,879,170 shares outstanding.
What happened to Context Therapeutics, Inc.’s price movement after its last earnings report?
Context Therapeutics, Inc. reported an EPS of -€0.078 in its last earnings report, beating expectations of -€0.096. Following the earnings report the stock price went up 1.523%.
Which hedge fund is a major shareholder of Context Therapeutics, Inc.?
Currently, no hedge funds are holding shares in DE:6K9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Context Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€5.46 (190.19% Upside)
€5.46 (190.19% Upside)
Blogger Sentiment
Bullish
DE:6K9 Sentiment 70%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
311.56%
12-Months-Change
Fundamentals
Return on Equity
-59.95%
Trailing 12-Months
Asset Growth
-36.69%
Trailing 12-Months
Company Description
Context Therapeutics, Inc.
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
6K9 Stock 12 Month Forecast
Average Price Target
€5.46
▲(190.19% Upside)
Technical Analysis
Options Prices
Currently, No data available
---